IP Library Granted Patent US 12,697,356
Granted Patent B2
US 12,697,356 · App. 16/627,195 · Granted Aug 4, 2026

Patent

Inventors: Stefan Pelzer (Gütersloh, DE); Daniel Petri (Vienna, AT); Christos Giatsis (Münster, DE); Stella Molck (Bielefeld, DE); Maike Kipker (Cologne, DE); Jessica Kleinbölting (Bielefeld, DE); Lorena Stannek-Göbel (Hannover, DE); Kiran Doranalli (Frankfurt, DE); John Khun Kyaw Htoo (Alzenau, DE); Claudia Borgmeier (Bensheim, DE); Sandra Herbold (Mannheim, DE); Guido Meurer (Seeheim-Jugenheim, DE)
Assignee: Evonik Operations GmbH
A61K35/742A23C9/1203A23C9/152A23C19/032A23C19/061A23K10/18A23K50/30A23K50/75A61P1/14C12N1/20C12N1/205A61K2035/115C12R2001/125
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,356
App. No.
16/627,195
Filed
Dec 27, 2019
Granted
Aug 4, 2026
Kind
B2
Art Unit
1651
USPC
424/93.46
Abstract

The current invention concerns a new B. subtilis strain with strong inhibition of swine and poultry related pathogens and its use as probiotic.

Claims (28)

1 . A feed or foodstuff comprising:

a) Bacillus subtilis DSM 32540;

b) at least one ingredient selected from the group consisting of: proteins, carbohydrates, fats, additional probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidiostats, acid-based products, medicines, and combinations thereof; and

c) at least one added carrier to improve one or more characteristics selected from the group consisting of: recovery; efficacy; physical properties; packaging and administration;

wherein:

i) when the feed or foodstuff is fed to an animal, the growth of pathogenic bacteria is reduced compared to growth in the feed or foodstuff without said Bacillus subtilis DSM 32540; and wherein said pathogenic bacteria are selected from the group consisting of: Clostridium perfringens, Clostridium difficile, Enterococcus cecorum, Streptococcus gallinaceus and Streptococcus suis bacteria; and

ii) said Bacillus subtilis DSM 32540 is able to grow in the presence of 2 mM bile.

2 . The feed or foodstuff of claim 1 , wherein said feed or foodstuff is a dry product and the added carrier is selected from the group consisting of: anti-caking agents; anti-oxidation agents; bulking agents; and protectants.

3 . The feed or foodstuff of claim 1 , wherein the Bacillus subtilis DSM 32540 is in the feed or foodstuff in an amount sufficient to reduce Clostridium perfringens growth in an animal gut by at least 0.5 log.

4 . The feed or foodstuff of claim 3 , wherein the Bacillus subtilis strain is present at 1×10 3 to 2×10 12 colony forming units (CFU) per gram of feed or foodstuff.

5 . A feed or foodstuff comprising a naturally non-occurring mutant of Bacillus subtilis DSM 32540, wherein said mutant is not found in nature and comprises a DNA sequence identity to DSM 32540 of at least 99.5%;

wherein:

i) said mutant of Bacillus subtilis DSM 32540 inhibits the growth of at least one of: Clostridium perfringens, Clostridium difficile, Enterococcus cecorum, Streptococcus gallinaceus and Streptococcus suis bacteria;

ii) said mutant of Bacillus subtilis DSM 32540 is able to grow in the presence of 2 mM bile; and

iii) the feed or foodstuff further comprises at least one ingredient selected from the group consisting of: proteins, carbohydrates, fats, additional probiotics, prebiotics, enzymes, vitamins, immune modulators, milk replacers, minerals, amino acids, coccidiostats, acid-based products, medicines, and combinations thereof and an added carrier selected from the group consisting of: anti-caking agents; anti-oxidation agents; bulking agents; and protectants;

wherein the mutant of Bacillus subtilis DSM 32540 is present in said feed or foodstuff in an amount sufficient to reduce pathogenic bacterial growth in an animal gut by at least 0.5 log compared to the same feed or foodstuff in the absence of the mutant of Bacillus subtilis DSM 32540.

6 . The feed or foodstuff of claim 5 , wherein said feed or foodstuff is a dry product and further comprises one or more carriers selected from the group consisting of: anti-caking agents; anti-oxidation agents; bulking agents; and protectants.

7 . The feed or foodstuff of claim 5 , wherein said feed or foodstuff inhibits or decreases the growth of Clostridium perfringens in said animal.

8 . The feed or foodstuff of claim 7 , wherein the mutant of Bacillus subtilis DSM 32540 is present at 1×10 3 to 2×10 12 CFU per gram of feed or foodstuff.

9 . The feed or foodstuff of claim 5 , wherein said mutant of Bacillus subtilis DSM 32540 exhibits a Clostridium perfringens strain ATCC 13124b1945, Streptococcus gallinaceus strain DSM 15349 and/or Streptococcus suis strain DSM 9682 clearance of at least 10 mm in a well diffusion antagonism assay on agar plates prepared with LB medium that is supplemented with trace elements of DSMZ media 1032.

10 . The feed or foodstuff of claim 5 , wherein the mutant of Bacillus subtilis DSM 32540 is present in the feed or foodstuff in an amount sufficient to reduce the growth of Clostridium perfringens, Clostridium difficile, Enterococcus cecorum, Streptococcus gallinaceus and Streptococcus suis bacteria by at least 1 log in infected animals administered a diet of the feed or foodstuff on a daily basis or to reduce the mortality of infected animals by at least 2% compared to animals administered the same diet but where the feed or foodstuff does not comprise the Bacillus subtilis mutant.

11 . The feed or foodstuff of claim 5 , wherein said mutant of B. subtilis DSM 32540 is a genetically engineered bacteria or said mutant has a mutation resulting from growing bacteria in the presence of a mutagen.

12 . A feed or foodstuff comprising fermentation products that comprise B. subtilis DSM 32540 and

wherein, when the feed or foodstuff is fed to an animal, it inhibits the growth of at least one of: Clostridium perfringens, Clostridium difficile, Enterococcus cecorum, Streptococcus gallinaceus and Streptococcus suis bacteria compared to growth when the feed or foodstuff is without said Bacillus subtilis DSM 32540; and

wherein the Bacillus subtilis DSM 32540 is present in the feed or foodstuff in an amount sufficient to reduce pathogenic bacterial growth in an animal gut by at least 0.5 log when fed to said animal.

13 . The feed or foodstuff of claim 12 , further comprising one or more carriers selected from the group consisting of: anti-caking agents; anti-oxidation agents; and bulking agents.

14 . The feed or foodstuff of claim 12 , wherein the Bacillus subtilis strain is present at 1×10 3 to 2×10 12 CFU per gram of composition.

15 . The feed or foodstuff of claim 13 , wherein the added carrier is an anti-caking agent or a bulking agent and the composition is a dry product.

Assignments (2)
CHANGE OF NAME Recorded Mar 10, 2020
From: EVONIK DEGUSSA GMBH
To: EVONIK OPERATIONS GMBH
Reel/Frame 052137/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2020
From: PELZER, STEFAN; PETRI, DANIEL; GIATSIS, CHRISTOS; MOLCK, STELLA; KIPKER, MAIKE; KLEINBÖLTING, JESSICA; STANNEK-GÖBEL, LORENA; DORANALLI, KIRAN; HTOO, JOHN KHUN KYAW; BORGMEIER, CLAUDIA; HERBOLD, SANDRA; MEURER, GUIDO
To: EVONIK DEGUSSA GMBH
Reel/Frame 051997/0272 →
Priority Claims (2)
EP 17179052 · Jun 30, 2017 · regional
CN 201710618158.9 · Jul 26, 2017 · national
Continuity (1)
Related Publication 20200113952A1 · Apr 16, 2020
References Cited (171)
US 4919936A · Iwanami et al. · 1990 [cited by applicant]
US 5227294A · Carrera et al. · 1993 [cited by applicant]
US 6060050A · Brown et al. · 2000 [cited by applicant]
US 6060051A · Heins et al. · 2000 [cited by applicant]
US 6194193B1 · Drahos et al. · 2001 [cited by applicant]
US 6849256B1 · Farmer · 2005 [cited by applicant]
US 7247299B2 · Lin et al. · 2007 [cited by applicant]
US 7981659B2 · Kadoya et al. · 2011 [cited by applicant]
US 9247757B2 · Schmidt et al. · 2016 [cited by applicant]
US 9622484B2 · Taghavi et al. · 2017 [cited by applicant]
US 9844573B2 · Nielsen et al. · 2017 [cited by applicant]
US 10138444B2 · Ayangbile et al. · 2018 [cited by applicant]
US 10702560B2 · Nielsen et al. · 2020 [cited by applicant]
US 10736925B2 · Khuong Huu et al. · 2020 [cited by applicant]
US 11173184B2 · Petri et al. · 2021 [cited by applicant]
US 11931385B2 · Isaksen et al. · 2024 [cited by applicant]
US 20080057047A1 · Sas et al. · 2008 [cited by applicant]
US 20120328571A1 · Schmidt · 2012 [cited by examiner]
US 20140010792A1 · Rehberger et al. · 2014 [cited by applicant]
US 20140065672A1 · Brune et al. · 2014 [cited by applicant]
US 20140342437A1 · Carpenter et al. · 2014 [cited by applicant]
US 20160326034A1 · Showell et al. · 2016 [cited by applicant]
US 20170073620A1 · Ayangbile et al. · 2017 [cited by applicant]
US 20170340683A1 · Petri et al. · 2017 [cited by applicant]
US 20210163357A1 · Müeller et al. · 2021 [cited by applicant]
US 20210228653A1 · Petri et al. · 2021 [cited by applicant]
US 20210392935A1 · Speckmann et al. · 2021 [cited by applicant]
US 20220088091A1 · Ochrombel et al. · 2022 [cited by applicant]
US 20220117264A1 · Giatsis et al. · 2022 [cited by applicant]
US 20220168363A1 · Stannek-Göebel et al. · 2022 [cited by applicant]
US 20220217998A1 · Riesen et al. · 2022 [cited by applicant]
US 20220241176A1 · Dieck et al. · 2022 [cited by applicant]
US 20230059825A1 · Giatsis et al. · 2023 [cited by applicant]
US 20230128187A1 · Speckmann et al. · 2023 [cited by applicant]
CN 105969708 · 2016 [cited by applicant]
CN 106906169 · 2017 [cited by applicant]
EP 0287699 · 1988 [cited by applicant]
EP 1010754 · 2000 [cited by applicant]
EP 1576120 · 2009 [cited by applicant]
JP 2000135096 · 2000 [cited by applicant]
JP 2003190993 · 2003 [cited by applicant]
JP 2015513910 · 2015 [cited by applicant]
KR 20080051798 · 2008 [cited by applicant]
KR 101467250 · 2014 [cited by applicant]
WO WO9828408 · 1998 [cited by applicant]
WO WO0043503 · 2000 [cited by applicant]
WO WO03066847 · 2003 [cited by applicant]
WO WO2013151361 · 2013 [cited by applicant]
WO WO2016108974 · 2016 [cited by applicant]
WO WO2017048636 · 2017 [cited by applicant]
WO WO2017044953A1 · 2017 [cited by examiner]
WO WO2017136944 · 2017 [cited by applicant]
WO WO2017207371 · 2017 [cited by applicant]
WO WO2017207372 · 2017 [cited by applicant]
WO WO2018045004 · 2018 [cited by applicant]
WO WO2019002471 · 2019 [cited by applicant]
WO WO2019002476 · 2019 [cited by applicant]
WO WO2019038153 · 2019 [cited by applicant]
WO WO2019063669 · 2019 [cited by applicant]
WO WO2022184637 · 2022 [cited by applicant]
WO WO2022184643 · 2022 [cited by applicant]
WO WO2023066533A1 · 2023 [cited by applicant]
Li et al., “Bacillus subtilis RZ001 improves intestinal integrity and alleviates colitis by inhibiting the Notch signalling pathway and activating ATOH-1”, Pathogens and Disease 2020, vol. 78, pp. 1-13 (Year: 2020). [cited by examiner]
Irfan et al., “Optimization of process parameters for xylanase production by [cited by examiner]
“Feed”; Encyclopædia Britannica. https://www.britannica.com/topic/feed-agriculture (accessed on Mar. 3, 2024) (Year: 2024). [cited by examiner]
Allos, “ [cited by applicant]
Chatterjee, et al., “ [cited by applicant]
Colles, et al., “Dynamics of [cited by applicant]
Farzanfar, et al., “The use of probiotics in shrimp aquaculture,” [cited by applicant]
Huang, et al., “Characterization of novel [cited by applicant]
Mishra, et al., “Current Challenges of [cited by applicant]
Pulkkinen, et al., “Intensive fish farming and the evolution of pathogen virulence: the case of columnaris disease in Finland,” [cited by applicant]
Vaseeharan, et al., “Control of pathogenic [cited by applicant]
U.S. Appl. No. 17/421,917, filed Jul. 9, 2021, US-2022/0117264 A1, Apr. 21, 2022, Giatsis. [cited by applicant]
U.S. Appl. No. 17/792,582, filed Jul. 13, 2022, Giatsis. [cited by applicant]
International Search Report for PCT/EP2017/062497 filed May 24, 2017 corresponding to copending U.S. Appl. No. 15/607,534. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/EP2017/062497 filed May 24, 2017 corresponding to copending U.S. Appl. No. 15/607,534. [cited by applicant]
International Preliminary Report on Patentability for PCT/EP2017/062497 filed May 24, 2017 corresponding to copending U.S. Appl. No. 15/607,534. [cited by applicant]
Non Final Office Action mailed May 18, 2020 for copending U.S. Appl. No. 15/607,534. [cited by applicant]
Hoang, et al., “Recombinant Bacillus subtilis Expressing the Clostridium perfringens Alpha Toxoid is a Candidate Orally Delivered Vaccine against Necrotic Enteritis,” [cited by applicant]
Jayaraman, et al., “Bacillus subtilis PB6 improves intestinal health of broiler chickens challenged with Clostridium perfringens-induced necrotic enteritis,” [cited by applicant]
Argenzio, R.A., Secretion of the Stomach and Accessory Glands, p. 405-418. In: Reece, W.O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 25; Cornell University Press, Ithaca, New York, (2004). [cited by applicant]
Argenzio, R.A., Digestive and Absorptive Functions of the Intestines, p. 419-437. In: Reece, W.O. (ed.), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 26; Cornell University Press, Ithaca, New York, (2… [cited by applicant]
Chen, et al., “Structural and Functional Characterization of Three Polyketide Synthase Gene Clusters in [cited by applicant]
Cutting, et al., Genetic Analysis (Chapter 2) In: Harwood CR, Cutting S M editors. Molecular Biological Methods for [cited by applicant]
Hossain, et al., “Effect of [cited by applicant]
Knap et al., “ [cited by applicant]
Lumpkins, et al., “Evaluation of Distillers Dried Grains with Solubles as a Feed Ingredient for Broilers,” [cited by applicant]
M'Sadeq, et al., “Towards the control of necrotic enteritis in broiler chickens with in-feed antibiotics phasing-out worldwide,” [cited by applicant]
Ohno, et al., “Production of a Lipopeptide Antibiotic, Surfactin, by Recombinant [cited by applicant]
Reddy, et al., “Effective feather degradation and keratinase production by [cited by applicant]
Rushen, et al., “Animal Behavior and Well-Being Symposium: Farm animal welfare assurance: Science and application,” [cited by applicant]
Savva, et al., “Molecular Architecture and Functional Analysis of NetB, a Pore-forming Toxin from [cited by applicant]
Scholz, et al., “Plantazolicin, a Novel Microcin B17/Streptolysin S-Like Natural Product from [cited by applicant]
Sel Vam, et al., “Effect of [cited by applicant]
Timbermont, et al., “Necrotic enteritis in broilers: an updated review on the pathogensis,” [cited by applicant]
Trampel, et al., Avian Digestion, pp. 488-500. In: Reece, W.O. (ed), Duke's Physiology of Domestic Animals; Twelfth Edition, Chapter 29; Cornell University Press, Ithaca, New York, USA (2004). [cited by applicant]
Uzal, et al., “Towards an understanding of the role of [cited by applicant]
Wang, et al., “Comparison of gyrB gene sequences, 16S rRNA gene sequences and DNA-DNA hybridization in the [cited by applicant]
Zhou, et al., “Effects of [cited by applicant]
Gao, et al., “Isolation of [cited by applicant]
Nithya, et al., Evaluation of the probiotic characteristics of [cited by applicant]
Final Office Action for copending U.S. Appl. No. 15/607,534, mailed Nov. 19, 2020. [cited by applicant]
Request for Continued Examination for copending U.S. Appl. No. 15/607,534, filed Mar. 19, 2021. [cited by applicant]
Amendment & Response to Accompany RCE for copending U.S. Appl. No. 15/607,534, filed Mar. 19, 2021. [cited by applicant]
Bishnoi, et al., “Draft Genome Sequence of a Natural Root Isolate, [cited by applicant]
U.S. Appl. No. 17/250,341, filed Jan. 7, 2021, US-2021/0163357 A1, Jun. 3, 2021, Müeller. [cited by applicant]
U.S. Appl. No. 17/049,155, filed Oct. 20, 2020, US-2022/0088091 A1, Mar. 24, 2022, Ochrombel. [cited by applicant]
U.S. Appl. No. 17/296,465, filed May 24, 2021, US-2021/0392935 A1, Dec. 23, 2021, Speckmann. [cited by applicant]
U.S. Appl. No. 17/608,274, filed Nov. 2, 2021, US-2022/0217998 A1, Jul. 14, 2022, Riesen. [cited by applicant]
U.S. Appl. No. 17/429,905, filed Aug. 10, 2021, US-2022/0168363 A1, Jun. 2, 2022, Stannek-Göebel. [cited by applicant]
U.S. Appl. No. 17/625,955, filed Jan. 10, 2022, US-2022/0241176 A1, Aug. 4, 2022, Dieck. [cited by applicant]
International Search Report for PCT/EP2018/067422, filed Jun. 28, 2018; corresponding to U.S. Appl. No. 16/627,195. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/EP2018/067422, filed Jun. 28, 2018; corresponding to U.S. Appl. No. 16/627,195. [cited by applicant]
International Preliminary Report on Patentability for PCT/EP2018/067422, filed Jun. 28, 2018; corresponding to U.S. Appl. No. 16/627,195. [cited by applicant]
International Search Report for PCT/EP2017/062495 filed May 24, 2017, corresponding to copending application U.S. Appl. No. 16/305,811. [cited by applicant]
Written Opinion of the International Searching Authority for PCT/EP2017/062495 filed May 24, 2017, corresponding to copending application U.S. Appl. No. 16/305,811. [cited by applicant]
International Preliminary Report on Patentability for PCT/EP2017/062495 filed May 24, 2017, corresponding to copending application U.S. Appl. No. 16/305,811. [cited by applicant]
European Search Report for European application EP 16 17 2164 dated Nov. 28, 2016 (corresponding to copending U.S. Appl. No. 15/607,534). [cited by applicant]
Restriction Requirement for copending U.S. Appl. No. 15/607,534, mailed Sep. 14, 2018. [cited by applicant]
Response to Restriction Requirement for copending U.S. Appl. No. 15/607,534, filed Nov. 20, 2018. [cited by applicant]
Office Action for copending U.S. Appl. No. 15/607,534, mailed Apr. 8, 2019. [cited by applicant]
Amendment and Response to Accompany RCE for copending U.S. Appl. No. 15/607,534, filed Feb. 10, 2020. [cited by applicant]
Bacillus subtilis 16S rDNA sequence; NCBI Reference Sequence: NR_112116.2; retrieved Feb. 8, 2020. [cited by applicant]
Bacillus subtilis groEL sequence; NCBI Reference Sequence: NR_000964.3; retrieved Feb. 8, 2020. [cited by applicant]
Bacillus subtilis gyrB sequence; NCBI Reference Sequence: NR_000964.3; retrieved Feb. 8, 2020. [cited by applicant]
Bacillus subtilis rpoB sequence; NCBI Reference Sequence: NR_000964.3; retrieved Feb. 8, 2020. [cited by applicant]
Bacillus subtilis yqfD sequence; GenBank: D84432.1; retrieved Feb. 8, 2020. [cited by applicant]
XP-002764349; Bacillus licheniforms strain BCRC 15413 a6S ribosomal RNA gene, partial sequence, last updated Aug. 14, 2007. [cited by applicant]
Allaart, et al., “Net B-producing and beta2-producing [cited by applicant]
Aluwong, et al., “Effect of Yeast Probiotic on Growth, Antioxidant Enzyme Activities and Malondialdehyde Concentration of Broiler Chickens,” [cited by applicant]
Beauchamp, et al., “Superoxide Dismutase: Improved Assays and an Assay Applicable to Acrylamide Gels,” [cited by applicant]
Bradford, “A Rapid and Sensitive Method for the Quatitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding,” [cited by applicant]
Collins, et al., “ [cited by applicant]
Den Besten, et al., “Phenotypic and Transcriptomic Analyses of Mildly and Severly Salt-Stressed [cited by applicant]
Glaser, et al., “Identification and Isolation of a Gene Required for Nitrate Assimilation and Anaerobic Growth of [cited by applicant]
Goyette-Desjardins, et al., “ [cited by applicant]
Kense, et al., “ [cited by applicant]
Larsen, et al., “Characterization of [cited by applicant]
Lin, et al., “Acute heat stress induces oxidative stress in broiler chickens,” [cited by applicant]
Mishra, et al., “Probiotics as Potential Antioxidants: A Systematic Review,” [cited by applicant]
Oelschlaeger, “Mechanisms of probiotic action—A review,” [cited by applicant]
Palop, et al., “Influence of pH on heat resistance of [cited by applicant]
Parente, et al., “A comparison of methods for the measurement of bacteriocin activity,” [cited by applicant]
Songer, et al., “Clostridial enteric infections in pigs,” [cited by applicant]
Songer, et al., “Infection of neonatal swine with [cited by applicant]
Teo, et al., “Inhibition of [cited by applicant]
Woodbury, et al., “An Improved Procedure Using Ferricyanide for Detecting Catalase Isozymes,” [cited by applicant]
U.S. Appl. No. 15/607,534, filed May 29, 2017, US-2017-0340683 A1, Nov. 30, 2017, Petri. [cited by applicant]
U.S. Appl. No. 16/305,811, filed Nov. 29, 2018, Petri. [cited by applicant]
Bampidis, et al., (EFSA Panel on Additives and Products or Substrates used in Animal Feed), “Safety and efficacy of [cited by applicant]
Hong, et al., “The use of bacterial spore formers as probiotics,” [cited by applicant]
“Bacillus subtilis strain UD1022, complete genome,” Feb. 28, 2016; retrieved from the internet Mar. 31, 2021; https://www.ncbi.nlm.nih.gov/nuccore/CP011534.1?report=fasta. [cited by applicant]
Notice of Allowance for copending U.S. Appl. No. 15/607,534, mailed Jul. 19, 2021. [cited by applicant]
Response to Non Final Office Action for copending U.S. Appl. No. 15/607,534, filed Sep. 16, 2020. [cited by applicant]
U.S. Appl. No. 17/788,239, filed Jun. 22, 2022, US-2023/0128187 A1, Apr. 27, 2023, Speckmann. [cited by applicant]
Lalloo, et al., “Isolation and selection of [cited by applicant]
Alignment KY244143.1 with instant Seq Id No. 1 (Year 2025). [cited by applicant]
Macwilliams, M. P et al. ASM “Luria Broth (LB) and Luria Agar (LA) Media and Their Uses Protocol,” published in 2016, pp. 1-4, downloaded from https://asm.org/protocols/luria-broth-lb-and-agar-la-media-and-their-u (Year… [cited by applicant]
Cho, et al., “In vitro degradation of zearaleone by Bacillus subtilis,” published on Aug. 10, 2010, Biotechnol. Lett. Vol. 32, pp. 1921-1924 (Year 2010). [cited by applicant]
Crab, et al., “Bio-flocs technology application in over-wintering of tilapia,” published in 2009,Aquaculture Engineering vol. 40, pp. 105-112. (year 2009). [cited by applicant]
Guisinger, et al., “Amino Acid Immobilization of Copper Surface Diffusion on Cu(111),” published Mar. 12, 2019, Adv. Mater. Interfaces, vol. 6, 1900021, pp. 1-8. (year 2019). [cited by applicant]
Liu, et al., “Dietary administration of Bacillus subtilis HAINUP40 enhances growth, digestive enzyme activities, inate immune responses and disease resistance of tilapia, Oreochromis niloticus,” published on Dec. 2, 201… [cited by applicant]
MedlinePlus (“Bile”, published on Jul. 15, 2017, downloaded from https://Aweb.archive.org/web/20170715220014/https:// medlineplus.gov/ency/article/002237.htm (Year 2017). [cited by applicant]
Nicholson, et al., “Exploring the Low-Pressure Growth Limit: Evolution of Bacillus subtilis in the Laboratory to Enhanced Growth at 5 Kilopascals,” published on Oct. 1, 2010, Appl. Environ. Microbiol. Vol. 72, No. 22, p… [cited by applicant]
Pirofsky, et al., “Q&A: What is a pathogen? A question that begs the point,” published on Jan. 31, 2012, BMC Biology vol. 10, No. 6, pp. 1-3. (Year 2012). [cited by applicant]
Sakata, et al., “Factors affecting the germination of Bacillus subtilis spores,” published in 1975, Mem. Fac. Fish., Kagoshima Univ., vol. 24, pp. 139-147. (Year 1975). [cited by applicant]
Schrein, “What is an animal?” published on Feb. 5, 2016, downloaded from https://www.sapiens.org/biology/what-is-an-animal/. (Year 2016). [cited by applicant]
Shifeng, et al., “ [cited by applicant]
Xia, et al., “Isolation and characterization of a Bacillus subtilis strain with aflatoxin B1 biodegradation capability,” published on Dec. 26, 2016, Food Control, vol. 75, pp. 92-98 (Year 2016). [cited by applicant]
Ye, et al., “Global Gene Expression Profiles of Bacillus subtilis Grown under Anaerobic Conditions,” published in Aug. 2000, Journal of Bacteriology, vol. 182, No. 16, pp. 4458-4465. (Year 2000). [cited by applicant]